Article
PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers.
ESMO open - 1 Oct 2021
Dumbrava E E, Call S G, Huang H J, Stuckett A L, Madwani K, Adat A, Hong D S, Piha-Paul S A, Subbiah V, Karp D D, Fu S, Naing A, Tsimberidou A M, Moulder S L, Koenig K H, Barcenas C H, Kee B K, Fogelman D R, Kopetz E S, Meric-Bernstam F, Janku F
Abstract excerpt
BACKGROUND: Oncogenic mutations in PIK3CA are prevalent in diverse cancers and can be targeted with inhibitors of the phosphoinositide-3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway. Analysis of circulating tumor DNA (ctDNA) provides a minimally invasive approach to detect clinically actionable PIK3CA mutations. PATIENTS AND METHODS: We analyzed PIK3CA hotspot mutation frequency...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.